PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Compare>>BPC-157 vs TB-500 (Thymosin Beta-4 Fragment)

BPC-157 vs TB-500 (Thymosin Beta-4 Fragment)

BPC-157 and TB-500 are the two compounds most often discussed together in tissue-repair contexts — and they are frequently sold as a blend. This comparison separates what each has in evidence, mechanism, and risk, and what the combination claim actually rests on.

BPC-157

Preclinical

A synthetic pentadecapeptide fragment of a protein found in human gastric juice, widely discussed for tissue healing. Its evidence base is almost entirely preclinical — rodent and cell-culture studies — with no completed randomized human trials.

Full entry →

TB-500 (Thymosin Beta-4 Fragment)

Preclinical

A synthetic fragment of thymosin beta-4, an actin-binding protein involved in cell migration and wound repair. Marketed products may contain the fragment or, in some cases, the full-length protein — a labeling inconsistency worth noting.

Full entry →

Evidence

Both compounds rest almost entirely on preclinical work. BPC-157 has a larger and more criticized rodent literature, including the frequently cited rat Achilles tendon study; TB-500’s base is smaller and its product-labeling consistency is worse. Neither has completed a controlled human outcome trial — the single most important fact about both.

Mechanism

BPC-157 is a gastric-juice-protein fragment proposed to influence fibroblast migration, angiogenesis, and nitric-oxide signaling. TB-500 is a thymosin beta-4 fragment participating in actin regulation and cell migration. The mechanisms are different enough that "stacking" them is a hypothesis, not a pharmacological argument.

Safety

Both lack human safety databases. The practical risks are identical: unverified product identity, unverified sterility, and no pharmacovigilance. Blends add an uncontrolled dose ratio on top.

The combination claim

No study — of any species — has tested the combination. Vendor "synergy" language is marketing. If a future trial tests the pair, this page will say so; today it cannot.

Frequently Asked Questions

Which one has better human evidence?

Neither. Both are preclinical-stage compounds. Any source claiming a human trial base for either is misrepresenting the literature.

Is the blend safer or riskier than either alone?

Riskier in a specific, boring way: two active compounds at an unspecified ratio, with the same zero human safety data as each component.

Educational comparison only — not medical advice and not a recommendation for either compound.
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement